Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 6
Journal homepage
237
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Dyslipidemia treatment in African–Americans:should race be a factor?

George Keith C FerdinandAssociation of Black Cardiologists, 5355 Hunter Road, Atlanta, GA 30349, USA, , Tel.: +1 404 201 6632; Fax.: +1 404 201 6601, E-mail: [email protected]Correspondence[email protected]
Pages 653-658 | Published online: 18 Jan 2017

  • Thom T, Haase N, Rosamand W et al.: Heart Disease and Stroke Statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics subcommittee. Circulation 113, E85–E151 (2006).
  • Caroll SB: Genetics and the making of Homosapiens. Nature 422(6934), 849–857 (2003).
  • Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention. Genomics and Population Health: United States (2003).
  • Arias E: United States life tables, 2003. National vital statistics reports; Vol 54 No 14. Hyattsville, MD: National Center for Health Statistics. (2006).
  • Murray CJL, Kulkarni SC, Michaud C et al.: Eight Americas: investigating mortality disparities across races, counties, and race counties in the United States. PloS Med. 3(9), E260 (2006).
  • Hayes DK, Greenlund KJ, Denny CH et al.: Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke – United States, 2003. MMWR 54, 113–117 (2005).
  • Whittle J, Kressin NR, Peterson ED et al.: Racial differences in the prevalence of coronary obstructions among with positive nuclear imaging studies. J. Am. Coll. Cardiol. 47, 2034–2041 (2006).
  • Liao Y, Ghali JK, Berzins L, Cooper RS: Coronary angiographic findings in African–American and white patients from a single institution. J. Natl Med. Assoc. 93(12), 465–474 (2001).
  • Strong JP, Oalmann MC, Newman WP 3rd et al.: Coronary heart disease in young African–American and white males in New Orleans: Community Pathology Study. Am. Heart J. 108(3 Pt 2), 747–759 (1984).
  • Tang W, Detrano RC, Brezden OS et al.: Racial differences in coronary calcium prevalence among high-risk adults. Am. J. Cardiol. 75(16), 1088–1091 (1995).
  • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
  • Vega GL, Clark LT, Tang A et al.: Hepatic lipase activity is lower in African American men than in white American men: effects of 5´ flanking polymorphism in the hepatic lipase gene (LIPC). J. Lipid Res. 39(1), 228–232 (1998).
  • Utermann G: The mysteries of lipoprotein(a). Science 246(4932), 904–910 (1989).
  • Rim L, Ali B, Slim BA, Bechir Z: Lipoprotein(a): a new risk factor for coronary artery disease. Tunis Med. 78(11), 648–652 (2000).
  • Parra HJ, Luyeye I, Bouramoue C et al.: African–American–white differences in serum Lp(a) lipoprotein levels. Clin. Chim. Acta 168(1), 27–31 (1987).
  • Moliterno DJ, Jokinen EV, Miserez AR et al.: No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African–Americans. Arterioscler. Thromb. Vasc. Biol. 15(7), 850–855 (1995).
  • Sorrentino MJ, Vielhauer C, Eisenbart JD et al.: Plasma lipoprotein (a) protein concentration and coronary artery disease in African–American patients compared with white patients. Am. J. Med. 93, 658–662 (1992).
  • Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein(a) levels and Apo(a) size and risk of coronary heart disease in Stanford Five- City Project participants. Arterioscler. Thromb. Vasc. Biol. 17, 239–245 (1997).
  • Sandholzer C, Saha N, Kark JD et al.: Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler. Thromb. 12, 1214–1226 (1992).
  • Marcovina SM, Albers JJ, Wijsman E et al.: Differences in Lp(a) concentrations and Apo(a) polymorphs between African–American and white Americans. J. Lipid Res. 37(12), 2569–2585 (1996).
  • Paultre F, Pearson TA, Weil HF et al.: High levels of Lp(a) with a small Apo(a) isoform are associated with coronary artery disease in African–American and white men. Arterioscler. Thromb. Vasc. Biol. 20(12), 2619–2624 (2000).
  • Drewnowski A, Specter SE: Poverty and obesity: the role of energy density and energy costs. Am. J. Clin. Nutr. 79(1), 6–16 (2004).
  • Erlinger TP, Vollmer WM, Svetkey LP et al.: The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African–Americans and hypertensives. Prev. Med. 37, 327–333 (2003).
  • Azadbakht L, Mirmiran P, Esmaillzadeh A et al.: Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care 28, 2823–2831 (2005).
  • Clark LT, Maki KC, Galant R et al.: Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel ETechnology II. J. Gen. Intern. Med. 21, 320–326 (2006).
  • Simon JA, Lin F, Hulley SB et al.: Phenotypic predictors of response to simvastatin therapy among African–Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol. 97, 843–850 (2006).
  • Ferdinand KC, Clark LT, Watson KE et al.: Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African–American patients in a 6-week trial. Am. J. Cardiol. 97, 229–235 (2006).
  • Ferdinand KC, Neal R, Ycas J et al.: Effect of ethnic origin, gender, and age on baseline blood creatine kinase. Presented at: 14th International Symposium on Atherosclerosis. Rome, Italy, 18–22 June 2006.
  • Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am. J. Cardiol. 97(8A), C69–C76 (2006).
  • Eichner JE, Dunn ST, Perveen G et al.: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155, 487–495 (2002).
  • Howard BV, Gidding SS, Liu K: Association of apolipoprotein E phenotype with plasma lipoproteins in African–American and white young adults. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am. J. Epidemiol. 148, 859–868 (1998).
  • Helgadottir A, Manolescu A, Helgason A et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicityspecific risk of myocardial infarction. Nat. Genet. 38(1), 68–74 (2006).
  • The Scandinavian Simvastatin Survival Study (4S).Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344, 1383–1389 (1994).
  • Shepherd J, Cobbe SM, Ford I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301–1317 (1995).
  • Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009 (1996).
  • The Long-term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349–1357 (1998).
  • Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615–1622 (1998).
  • HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
  • ALLHAT Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998–3007 (2002).
  • ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.